Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV cohort study

Antiviral Therapy

Volumn 15, Issue 3, 2010, Pages 413-423

  Marzolini, Catia ^a   Elzi, Luigia ^a   Gibbons, Sara ^b   Weber, Rainer ^c   Fux, Christoph ^d   Furrer, Hansjakob ^d   Chave, Jean Philippe ^e   Cavassini, Matthias ^e   Bernasconi, Enos ^f   Calmy, Alexandra ^g   Vernazza, Pietro ^h   Khoo, Saye ^b   Ledergerber, Bruno ^c   Back, David ^b   Battegay, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALFUZOSIN; ANTIINFECTIVE AGENT; ATAZANAVIR; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; DARIFENACIN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ESOMEPRAZOLE; FOSAMPRENAVIR; GINKGO BILOBA EXTRACT; ILLICIT DRUG; LAMIVUDINE; LERCANIDIPINE; LOPINAVIR; METHADONE; METOPROLOL; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RANITIDINE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; TRIAZOLAM; UNINDEXED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CENTRAL NERVOUS SYSTEM AGENTS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; AGE; ARTICLE; BRADYCARDIA; COHORT ANALYSIS; COMORBIDITY; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENDER; HEART ARRHYTHMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NONHUMAN; OBESITY; PANCREATITIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SWITZERLAND; COMPLICATION; DRUG COMBINATION; DRUG INTERACTION; HIV INFECTIONS; POLYPHARMACY;

ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; COHORT STUDIES; COMORBIDITY; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; METHADONE; POLYPHARMACY; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SWITZERLAND;

EID: 77952923349     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1540     Document Type: Article

References (29)

1. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
2. Antiretroviral therapy cohort collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
3. Simone MJ, Appelbaum J. HIV in older adults. Geriatrics 2008; 63:6-12.
4. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patient with HIV infection. Clin Pharmacokinet 1999; 36:289-304. (Pubitemid 29201737)
5. Kim RB. Drug transporters in HIV therapy. Top HIV Med 2003; 11:136-139.
6. Kiang TKL, Ensom MHH, Chang TKH. UDP-gluconosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106:97-132.
7. Marzolini C, Tirona RG, Lee W, et al. Unexpected complexity in nuclear receptor activation by HIV protease inhibitors and induction of CYP enzymes and transporters. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 135.
8. Béïque L, Giguère P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med 2007; 8:335-345. (Pubitemid 47163265)
9. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS 2004; 18:568-586. (Pubitemid 39431032)
10. de Maat MMR, Frankfort SV, Mathot RAA, et al. Discrepancies between medical and pharmacy records for patients on anti-HIV drugs. Ann Pharmacother 2002; 36:410-415.
11. Park-Wyllie LY, Levine MA, Holbrook A, et al. Outcomes of dosage adjustments used to manage antiretroviral drug interactions. Clin Infect Dis 2007; 45:933-936. (Pubitemid 47580391)
12. Shah S, McGowan J, Opulski B, Lieblein A, Saperstein A. Identification of drug interactions involving antiretroviral therapy (ART) in New York City HIV specialty clinics. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 573.
13. de Maat MMR, de Boer A, Koks CHW, et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther 2004; 29:121-130.
14. Kigen G, Kimaiyo S, Owen A, et al. Prevalence of drug interactions between antiretroviral and co-administered drugs in Kenya. 9th International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract O122.
15. Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007; 27:1379-1386. (Pubitemid 47530444)
16. Swiss HIV Cohort Study. (Accessed 4 March 2010.) Available from http://www.SHCS.ch
17. Liverpool HIV drug interactions. (Accessed 4 March 2010.) Available from http://www.hiv-druginteractions.org
18. Li L, Stanton JD, Tolson AH, Luo Y, Wang H. Bioactive terpenoids and flavonoids from ginkgo biloba extract induce the expression of hepatic drug metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 2009; 26:872-882.
19. Teotico DG, Bischof JJ, Peng L, Kliewer SA, Redinbo MR. Structural basis of human PXR activation by the hops constituent colupulone. Mol Pharmacol 2008; 74:1512-1520.
20. US Food and Drug Administration. (Accessed 4 March 2010.) Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
21. European Medicines Agency. (Accessed 4 March 2010.) Available from http://www.ema.europa.eu/htms/human/epar/eparintro.htm
22. Meade CS, Sikkema KJ. HIV risk behaviour among adults with severe mental illness: a systematic review. Clin Psychol Rev 2005; 25:433-457. (Pubitemid 40731527)
23. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
24. d'Arminio Monforte A, Cozzi-Lepri A, Castagno A, et al. Risk of developing specific AIDS defining illnesses in patients co-infected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009; 49:612-622.
25. Mohsen AH, Murad S, Easterbrook PJ. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med 2005; 6:206-215. (Pubitemid 40740338)
26. Pham PA. Drug-drug interaction programs in clinical practice. Clin Pharmacol Ther 2008; 83:396-398.
27. Kiser J, Gerber J, Predhomme J, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47:570-578. (Pubitemid 351442013)
28. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 2008; 198:948-961.
29. GRADE working group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328:e1490.